<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20961967</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>01</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1479-683X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>164</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of endocrinology</Title>
                <ISOAbbreviation>Eur J Endocrinol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>69-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1530/EJE-10-0875</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Osteoprotegerin (OPG) acts as an important regulatory molecule in atherosclerosis. Recent studies report that thiazolidinediones could affect OPG expression. We investigated the relationship between OPG and inflammatory cytokines and the effects of pioglitazone (a PPARγ (PPARG) agonist) versus metformin on serum OPG levels in type 2 diabetic patients.</AbstractText>
                <AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">Sixty-seven type 2 diabetic patients were included in this study. They were assigned to pioglitazone (15 mg/day, n=34) or metformin (1000 mg/day, n=33) during 24 weeks. Various anthropometric and metabolic parameters, OPG, interleukin 6 (IL6), C-reactive protein (CRP), adiponectin, and homeostasis model assessment of insulin resistance (HOMA-IR), were measured at baseline and at 6 months of treatment.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum OPG levels correlated significantly with fasting plasma glucose (FPG), HbAlc, HOMA-IR, IL6, and CRP, and inversely correlated with adiponectin after adjusting for age (P&lt;0.05). Multiple regression analysis showed that FPG, HbAlc, and adioponectin were independently correlated with OPG level. After 6 months of treatment, the reduction in FPG and HbAlc levels was similar between the two groups. Pioglitazone treatment significantly increased body mass index (P&lt;0.05) and waist circumference (P&lt;0.05) and decreased triglycerides (P&lt;0.05) and HOMA-IR (P&lt;0.01). The adiponectin concentration was increased (P&lt;0.05), and OPG and CRP levels were decreased in the pioglitazone group (P&lt;0.05), but were unchanged in the metformin group. The changes in serum OPG in the pioglitazone group showed significant correlation with changes in FPG, HbAlc, and adiponectin.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In type 2 diabetic patients, pioglitazone decreases OPG levels, and this decrease in OPG levels might be associated with the increase in adiponectin.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Jong Suk</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Endocrinology, Department of Internal Medicine, Kangnam Severance Hospital Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, 146-92, Dogok-Dong, Kangnam-Ku, Seoul 135-720, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cho</LastName>
                    <ForeName>Min Ho</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nam</LastName>
                    <ForeName>Ji Sun</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoo</LastName>
                    <ForeName>Jeong Seon</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Chul Woo</ForeName>
                    <Initials>CW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cha</LastName>
                    <ForeName>Bong Soo</ForeName>
                    <Initials>BS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Kyung Rae</ForeName>
                    <Initials>KR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Hyun Chul</ForeName>
                    <Initials>HC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Endocrinol</MedlineTA>
            <NlmUniqueID>9423848</NlmUniqueID>
            <ISSNLinking>0804-4643</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D052242">Adiponectin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053244">Osteoprotegerin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-41-4</RegistryNumber>
                <NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9100L32L2N</RegistryNumber>
                <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>X4OV71U42S</RegistryNumber>
                <NameOfSubstance UI="D000077205">Pioglitazone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D052242" MajorTopicYN="N">Adiponectin</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007333" MajorTopicYN="N">Insulin Resistance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053244" MajorTopicYN="N">Osteoprotegerin</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077205" MajorTopicYN="N">Pioglitazone</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20961967</ArticleId>
            <ArticleId IdType="pii">EJE-10-0875</ArticleId>
            <ArticleId IdType="doi">10.1530/EJE-10-0875</ArticleId>
            <ArticleId IdType="pmc">PMC3000683</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 2003 Mar;88(3):1024-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12629080</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Endocrinol. 2003 Jul;149(1):39-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12824864</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2001 Jun 8;276(23):20659-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11274143</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):717-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12006382</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2002 Jun 14;294(3):597-601</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12056809</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drugs. 2002;62(10):1463-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12093315</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Circulation. 2002 Sep 3;106(10):1192-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12208791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Med. 2004 Mar 22;116 Suppl 6A:9S-16S</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15050187</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Circulation. 2004 May 11;109(18):2175-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15117849</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15173056</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2004 Sep 9;351(11):1106-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15356308</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Nutr. 2004 Oct;23(5):963-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15380884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 1979 May 11;241(19):2035-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">430798</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 1997 May 8;234(1):137-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9168977</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>FASEB J. 1998 Jul;12(10):845-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9657524</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Endocrinol. 2008 Mar;158(3):353-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18299469</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diabetes Care. 2008 Mar;31(3):593-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18083791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Endocrinol. 2009 Sep;161(3):451-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19542241</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Biochem. 2009 Sep;42(13-14):1375-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19523465</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Circulation. 1999 Dec 21-28;100(25):2473-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10604883</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 2000 Jul;85(7):2355-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10902778</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biochem. 1999 Sep 1;74(3):357-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10412038</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Coll Cardiol. 2005 Jun 21;45(12):1925-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15963388</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Horm Metab Res. 2005 May;37(5):297-302</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15971153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diabetes Care. 2005 Sep;28(9):2176-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16123486</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Endocrinol (Oxf). 2005 Nov;63(5):594-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16268814</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Endocrinol (Oxf). 2006 Jun;64(6):652-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16712667</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diabetes. 2006 Jul;55(7):2126-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16804084</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Bone Miner Res. 2006 Oct;21(10):1648-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16995820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2001 Jan 12;280(1):334-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11162519</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 2001 Feb;86(2):631-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11158021</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):168-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12588755</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
